Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Arsenic trioxide (ATO) is one of the first-line chemotherapeutic drugs for acute promyelocytic leukemia. Its anti-cancer activities against various human neoplastic diseases have been extensively studied. However, the clinical use of ATO for solid tumors is limited, and these limitations are because...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mengzhen Yu, Yanwen Zhang, Meirong Fang, Shah Jehan, Wenhu Zhou
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2022-03-01
Col·lecció:Pharmaceutics
Matèries:
Arsenic trioxide
nanomedicines
bioavailability
cytotoxicity
synergistic effect
combinatorial treatment
Accés en línia:https://www.mdpi.com/1999-4923/14/4/743
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars